3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Heart -

Method to estimate LDL-C may provide more accurate risk classification

HeartNov 18, 13

Seth S. Martin, M.D., of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, and colleagues developed a method for estimating low-density lipoprotein cholesterol (LDL-C) levels that is more accurate than the standard measure.

Low-density lipoprotein cholesterol is the primary target for treatment in national and international clinical practice guidelines. Conventionally, LDL-C is estimated by the Friedewald equation, which estimates LDL-C as (total cholesterol) - (high-density lipoprotein cholesterol [HDL-C]) - (triglycerides/5) in mg/dL. The final term assumes a fixed ratio of triglyceride levels to very low-density lipoprotein cholesterol (TG:VLDL-C) of 5:1. “Applying a factor of 5 to every individual patient is problematic given variance in the TG:VLDL-C ratio across the range of triglyceride and non-HDL-C levels,” according to background information in the study.

The researchers used a sample of lipid profiles obtained from 2009 through 2011 from 1,350,908 children, adolescents, and adults in the United States.

From this large sample of lipid profiles, the authors created and validated a novel method to estimate LDL-C from the standard lipid profile, consisting of a 180-cell table (grid) of median TG:VLDL-C values based on triglyceride and non-HDL-C values. Rather than assuming a fixed factor of 5, it applies an adjustable factor for the TG:VLDL-C ratio based on triglyceride and non-HDL-C concentrations. “The greatest advantage occurs in classification of LDL-C concentrations lower than 70 mg/dL, especially in patients with elevated triglyceride concentrations. In addition to the novel analytic approach, a major strength of this study is its size, 3,015 times larger than the original Friedewald database.”

“These findings require external validation, as well as assessment of their clinical importance. The novel method could be easily implemented in most laboratory reporting systems at virtually no cost.”

###

(doi:10.l001/jama.2013.280532; Available pre-embargo to the media at http://media.jamanetwork.com)

Media Advisory: To contact Seth S. Martin, M.D., call Ellen Beth Levitt at 410-598-4711 or email .(JavaScript must be enabled to view this email address).

###

Ellen Beth Levitt
.(JavaScript must be enabled to view this email address)
410-598-4711
The JAMA Network Journals



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New superfoods could help key protein keep bodies healthy
  Mobile app on emergency cardiac care aids best decisions in seconds
  Train your heart to protect your mind
  Mass. General study identifies path to safer drugs for heart disease, cancer
  Tweaking MRI to track creatine may spot heart problems earlier, Penn Medicine study suggests
  Texting heart medication reminders improved patient adherence
  Hybrid heart valve is strong, durable in early tests
  Cardiopoietic ‘Smart’ Stem Cells Show Promise in Heart Failure Patients
  Vitamin D deficiency ups heart disease risk
  Heart surgery safe in Jehovah’s Witnesses
  Magnet helps target transplanted iron-loaded cells to key areas of heart
  Screening programs detect cases of undiagnosed rheumatic heart disease in low-resource countries

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site